4.8 Article

RLIP76: A Target for Kidney Cancer Therapy

期刊

CANCER RESEARCH
卷 69, 期 10, 页码 4244-4251

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-3521

关键词

-

类别

资金

  1. NIH [CA 77495, CA 104661, ES 012171]
  2. Cancer Research Foundation of North Texas
  3. Institute for Cancer Research and the Joe and Jessie Crump Fund for Medical Education

向作者/读者索取更多资源

RLIP76 is a multifunctional transporter protein that serves as an energy-dependent efflux mechanism for endogenously generated toxic metabolites as well as exogenous toxins, including chemotherapy drugs. Our recent studies in cultured cells, syngeneic animal tumor model, and in xenograft model have shown that RLIP76 serves a major cancer-specific antiapoptotic role in a wide variety of histologic types of cancer, including leukemia, melanoma, colon, lung, prostate, and ovarian cancer. Results of present studies in cell culture and xenograft model of Caki-2 cells show that RLIP76 is an important anticancer for kidney cancer because inhibition of RLIP76 function by antibody or its depletion by small interfering RNA or antisense DNA caused marked and sustained regression of established human kidney xenografts of Caki-2 cells in nude mouse. [Cancer Res 2009;69(10):,4244-51]

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据